NCT06010641 Trendelenburg Position for Acute Anterior Circulation Ischemic Stroke With Large Artery Atherosclerosis Etiology (HOPES 3)
| NCT ID | NCT06010641 |
| Status | Recruiting |
| Phase | — |
| Sponsor | General Hospital of Shenyang Military Region |
| Condition | Stroke, Acute Ischemic |
| Study Type | INTERVENTIONAL |
| Enrollment | 600 participants |
| Start Date | 2024-01-10 |
| Primary Completion | 2027-10-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 600 participants in total. It began in 2024-01-10 with a primary completion date of 2027-10-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The effect of head position as a nonpharmacological therapy on acute ischemic stroke (AIS) remains inconclusive. Recent HOPES2 (Head dOwn-Position for acutE moderate ischemic Stroke with large artery atherosclerosis) suggest the safety, feasibility, and potential benefit of the head-down position (HDP) in acute ischemic stroke. The current study aims to investigate the efficacy and safety of HDP in acute moderate ischemic stroke patients with large artery atherosclerosis.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years old * Acute ischemic stroke confirmed by NCCT or MRI; * Moderate neurologic deficit (6≤ NIHSS ≤ 16) within 24 hours of onset, or progressing from mild (NIHSS ≤ 5) to moderate neurologic deficit (6≤ NIHSS ≤ 16) within 24 hours, requiring ≥ 4 point increase in NIHSS score although the onset time is beyond 24 hours; * Probable large artery atherosclerosis etiology based on the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria (responsible artery stenosis ≥ 50% or occlusion); * Anterior circulation stroke (internal carotid artery, M1 or M2 of middle cerebral artery); * First stroke onset or past stroke without obvious neurological deficit (mRS≤2); * Signed informed consent. Exclusion Criteria: * Pre-stroke disability (mRS≥3); * Patients with disturbance of consciousness; * Patients who plan to undergo or have completed thrombolysis or mechanical thrombectomy; * Hemorrhagic stroke or combined ischemic and hemorrhagic stroke; * Serious comorbidity, such as liver or kidney insufficiency, malignant tumor, etc; * Other stroke etiologies, such as cardiogenic embolism, arteritis, arterial dissection, moyamoya disease, etc; * Previous history of intracerebral hemorrhage within 1 year; * Any contraindication to head-down position (e.g. active vomiting, pneumonia, uncontrolled heart failure); * Planned carotid or intracranial revascularization within 3 months; * Severe uncontrolled hypertension (systolic blood pressure over 180mmHg or diastolic blood pressure over 100 mmHg); * Cardiac insufficiency (NYHA Class ≥II); * Pregnant or lactating women; * Comorbidity with other serious diseases; * Participating in other clinical trials within 3 months; * Patients not suitable for the study considered by researcher.
Frequently Asked Questions
Who can join the NCT06010641 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke, Acute Ischemic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06010641 currently recruiting?
Yes, NCT06010641 is actively recruiting participants. Visit ClinicalTrials.gov or contact General Hospital of Shenyang Military Region to inquire about joining.
Where is the NCT06010641 trial being conducted?
This trial is being conducted at Shenyang, China.
Who is sponsoring the NCT06010641 clinical trial?
NCT06010641 is sponsored by General Hospital of Shenyang Military Region. The trial plans to enroll 600 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.